Affitech
↗Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)
Affitech was a human therapeutic antibody discovery and development company based in Copenhagen, Denmark with research facilities in Oslo, Norway and San Francisco Bay Area. Founded in 1997 by Norwegian and German scientists, the company pioneered proprietary antibody discovery platforms including its phagemid display technology (CBAS - Cell Based Antibody Selection, and MBAS - Molecule Based Antibody Screening). The company developed innovative technologies for the generation and use of fully human antibodies, with particular focus on oncology and cancer therapeutics. Affitech successfully partnered with major pharmaceutical companies including Roche, Peregrine Pharmaceuticals, and Omeros, leveraging its AffiScreen™ platform that utilized patient-derived antibody repertoires in high-throughput screening.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:1997
Ownership:private
Status:shutdown
FUNDING
Stage:Post-IPO
Total Raised:$13M
Investors:Teknoinvest, Ferd, Arendals Fossekompani, Braganza, Four Seasons Ventures
STOCK
Exchange:NASDAQ OMX Copenhagen
Ticker:AFFI
PIPELINE
Stage:Clinical
Lead Drug Stage:Phase 1 / Clinical development
Modalities:Monoclonal Antibodies, Full Human Antibodies, Antibody Fragments
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Trans Nova Investments Limited (post-acquisition)
Acquired By:Trans Nova Investments Limited (via conditional purchase offer in 2012) (2012-03-01)
Subsidiaries:Affitech Research AS (Oslo, Norway), Affitech USA
Key Partnerships:Roche: Antibody discovery collaboration for unnamed oncology target; generated $3M milestone payment when faricimab (VABYSMO) received EC approval for wAMD and DME, Peregrine Pharmaceuticals: License and development agreement for anti-VEGF antibodies; R84/AT001 lead asset from this partnership, Omeros Corporation: Antibody discovery for MASP-2 target; agreement included technology access fee, milestone payments, and royalties, Norwegian National Institute of Public Health: Collaboration on discovery and pre-clinical validation of human antibodies, DKFZ (German Cancer Research Centre): Exclusive worldwide license of phagemid antibody display system and Breitling patents
COMPETITION
Position:Emerging
Competitors:Genmab, MorphoSys, Morphotek (Soigen subsidiary), Regeneron Pharmaceuticals, Medimmune (AstraZeneca), Biogen, Celldex Therapeutics
LEADERSHIP
Key Executives:
Dr. Robert Burns - CEO
Dr. Alexander Duncan - Senior Vice President, Research & Development
Rathin Das - Chief Business Officer
Martin Welschof - Managing Director and Co-founder
Scientific Founders:Martin Welschof, Group of Norwegian and German Scientists
Board Members:Aleksandr Shuster (Chairman (2012)), Yegor S. Vassetzky (Vice Chairman (2012)), Dr. Keith McCullagh (Former Vice-Chairman / Chairman), Øyvind Brøymer (Former Chairman (2002-2010)), Dr. Andrei Petrov (Non-executive Director)
LINKS
Website:affitech.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Affitech. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.